C-QTELautologous regenerative cell therapy, adipose-derived regenerative cells, orthopedics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
InGeneron autologous regenerative cell therapy, adipose-derived regenerative cells, orthopedics
InGeneron is a Houston-headquartered biotechnology company formed to innovate cell-based technologies for health care and life science research. Its technology uses a patient's own regenerative cells, including adipose-derived regenerative cells, prepared with the Transpose Ultra process for therapeutic application. The company states that it is focused on evidence-based, FDA-approved therapies and does not treat patients outside approved clinical trials.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
InGeneron — Translational · Lower middle. Derived deterministically from 8 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic